KORU Medical Systems (NASDAQ:KRMD) Stock Rating Reaffirmed by Canaccord Genuity Group

Canaccord Genuity Group reiterated their buy rating on shares of KORU Medical Systems (NASDAQ:KRMD – Free Report) in a research note published on Thursday, Benzinga reports. They currently have a $3.00 price objective on the stock. KRMD has been the subject of a number of other reports. B. Riley initiated coverage on KORU Medical Systems […]

Leave a Reply

Your email address will not be published.

Previous post R1 RCM (NASDAQ:RCM) Receives Buy Rating from Canaccord Genuity Group
Next post Neurocrine Biosciences’ (NBIX) “Buy” Rating Reaffirmed at Canaccord Genuity Group